Esperion Therapeutics Inc. [ESPR] Revenue clocked in at $116.33 million, down -3.01% YTD: What’s Next?

Esperion Therapeutics Inc. [NASDAQ: ESPR] closed the trading session at $2.90. The company report on February 27, 2024 at 6:00 AM that Esperion Reports Fourth Quarter and Full Year 2023 Financial Results.

– FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3 Million; FY23 Total Revenue Grew 54% Y/Y to $116.3 Million –.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


– Q4 U.S. Net Product Revenue Grew 39% Y/Y to $20.8 Million; Q4 Total Revenue Grew 72% Y/Y to $32.3 Million –.

The stocks have a year to date performance of -3.01 percent and weekly performance of 8.21 percent. The stock has been moved at 110.14 percent over the last six months. The stock has performed 36.15 percent around the most recent 30 days and changed 132.00 percent over the most recent 3-months.

If compared to the average trading volume of 6.23M shares, ESPR reached to a volume of 9886139 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Esperion Therapeutics Inc. [ESPR]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ESPR shares is $8.27 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ESPR stock is a recommendation set at 1.57. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BofA Securities have made an estimate for Esperion Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 03, 2024. While these analysts kept the previous recommendation, JP Morgan raised their target price to Neutral. The new note on the price target was released on November 20, 2023, representing the official price target for Esperion Therapeutics Inc. stock. On June 15, 2023, analysts increased their price target for ESPR shares from 1.25 to 4.

The Average True Range (ATR) for Esperion Therapeutics Inc. is set at 0.25, with the Price to Sales ratio for ESPR stock in the period of the last 12 months amounting to 4.25.

ESPR stock trade performance evaluation

Esperion Therapeutics Inc. [ESPR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.21. With this latest performance, ESPR shares gained by 36.15% in over the last four-week period, additionally plugging by 110.14% over the last 6 months – not to mention a drop of -53.23% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ESPR stock in for the last two-week period is set at 67.10, with the RSI for the last a single of trading hit 74.45, and the three-weeks RSI is set at 63.56 for Esperion Therapeutics Inc. [ESPR]. The present Moving Average for the last 50 days of trading for this stock 2.47, while it was recorded at 2.68 for the last single week of trading, and 1.60 for the last 200 days.

Esperion Therapeutics Inc. [ESPR]: An insightful look at the core fundamentals

Esperion Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.21 and a Current Ratio set at 1.58.

Earnings per share (EPS) analysis for Esperion Therapeutics Inc. [ESPR] stock

With the latest financial reports released by the company, Esperion Therapeutics Inc. posted -0.76/share EPS, while the average EPS was predicted by analysts to be reported at -0.84/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 9.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ESPR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Esperion Therapeutics Inc. go to 16.90%.

Esperion Therapeutics Inc. [ESPR]: Institutional Ownership

The top three institutional holders of ESPR stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in ESPR stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in ESPR stock with ownership which is approximately 5.8325%.